• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Medical Device Market
    Medical Device News
    Medical Device Stocks
    • Medical Device Market
    • Medical Device News
    • Medical Device Stocks
    medical device investing

    Medigus Reaches 10 Patients in Chinese Trial

    Bryan Mc Govern
    Apr. 27, 2017 08:23AM PST
    Medical Device Investing

    Medigus announced there have now been 10 procedures for the MUSE device trial in China.

    Medigus (NASDAQ:MDGS) announced there have now been 10 procedures for the MUSE device trial in China.
    As quoted in the press release:

    “The availability of the MUSE™ procedure in China provides patients with a less invasive option for the long-term treatment of GERD,” said principal investigator, Yunsheng Yang, Director of Gastroenterology Department Clinical center at 301 Hospital and chairman of Chinese Society of Gastroenterology, The General Hospital of People’s Liberation Army in Beijing. “The procedure addresses a new hope and solution between drug therapy and surgical procedures.”
    Procedures for the clinical study, which will include approximately 62 patients, have begun at four centers across China:

    • The General Hospital of People’s Liberation Army
    • Renji Hospital of Shanghai
    • Shanghai General Hospital
    • Peking University Third Hospital

    Procedures are expected to continue through 2017, with results being reported to the CFDA in 2018 as part of the submission for clearance to sell MUSE™ in China.

    Click here to read the full press release.

    Source: www.marketwired.com

    drug therapyclinical studychinachina food and drug administrationmedical device investing
    The Conversation (0)

    Go Deeper

    AI Powered
    Stethoscope connected to a phone with medical data overlay.

    Top 5 Small-cap Medical Device Stocks (Updated January 2025)

    Doctor looking into a microscope

    5 Small Medical Device Companies

    Latest News

    More News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Medical Device Investing Stocks

    Cardiex Limited

    CDX:AU
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×